NCT06063317 2026-03-06
OASIS
Imugene Limited
Phase 1 Terminated
Clinical Trials
4 trialsNCT02811679 2025-05-23
A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT04506086 2025-05-18
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 4 Terminated
NCT04556084 2025-05-13
Blinatumomab Bridging Therapy for BALL
Medical College of Wisconsin
Phase 2 Terminated